✦ LIBER ✦

Pharmacotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus: Rationale and Specific Agents

✍ Scribed by Cefalu, W T; Waldman, S; Ryder, S

Book ID: 110020028
Publisher: Nature Publishing Group
Year: 2007
Tongue: English
Weight: 532 KB
Volume: 81
Category: Article
ISSN: 0009-9236
DOI: 10.1038/sj.clpt.6100156

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rationale and options for combination th

Rationale and options for combination therapy in the treatment of Type 2 diabetes

✍ L. Van Gaal; I. De Leeuw 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 180 KB

The occurrence of asthma in hospitalized

The occurrence of asthma in hospitalized patients with type 2 diabetes mellitus

✍ M. Hashemzadeh; M. R. Movahed 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 374 KB

Phosphodiesterase type 5 inhibitors for

Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus

✍ Vickers, M A; Satyanarayana, R 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 97 KB

Laparoscopic treatment of type 2 diabete

Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35

✍ A. L. DePaula; A. L. V. Macedo; N. Rassi; C. A. Machado; V. Schraibman; L. Q. Si 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 354 KB

Laparoscopic Duodenal–Jejunal Exclusion

Laparoscopic Duodenal–Jejunal Exclusion in the Treatment of Type 2 Diabetes Mellitus in Patients with BMI < 30

✍ Almino C. Ramos; Manoel P. Galvão Neto; Yglésio Moyses de Souza; Manoela Galvão; 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 153 KB

Pravastatin compared to bezafibrate in t

Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitus

✍ C. Rustemeijer; J. A. Schouten; H. J. Voerman; H. E. S. J. Hensgens; A. J. M. Do 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

Background Both HMG-CoA reductase inhibitors and ®bric acid derivates are used for the treatment of dyslipidemia in Type 2 diabetes patients. The aim of this study was to compare the lipid lowering effect of 40 mg pravastatin, a HMG-CoA reductase inhibitor, and 400 mg beza®brate, a ®bric acid deriva